Please use this identifier to cite or link to this item:
Title: Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.
Austin Authors: Courage, Carolina;Oliver, Karen L;Park, Eon Joo;Cameron, Jillian M ;Grabińska, Kariona A;Muona, Mikko;Canafoglia, Laura;Gambardella, Antonio;Said, Edith;Afawi, Zaid;Baykan, Betul;Brandt, Christian;di Bonaventura, Carlo;Chew, Hui Bein;Criscuolo, Chiara;Dibbens, Leanne M;Castellotti, Barbara;Riguzzi, Patrizia;Labate, Angelo;Filla, Alessandro;Giallonardo, Anna T;Berecki, Geza;Jackson, Christopher B;Joensuu, Tarja;Damiano, John A;Kivity, Sara;Korczyn, Amos;Palotie, Aarno;Striano, Pasquale;Uccellini, Davide;Giuliano, Loretta;Andermann, Eva;Scheffer, Ingrid E ;Michelucci, Roberto;Bahlo, Melanie;Franceschetti, Silvana;Sessa, William C;Berkovic, Samuel F ;Lehesjoki, Anna-Elina
Affiliation: Neurogenetics Unit and Epilepsy Research Group, Montreal Neurological Hospital and Institute, Montreal, QC H3A 2B4, Canada; Departments of Neurology & Neurosurgery and Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada
Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry Massachusetts General Hospital, Boston, MA 02114, USA
Section of Medical Genetics, Mater dei Hospital, Msida MSD2090, Malta
Department of Anatomy and Cell Biology, University of Malta, Msida MSD2090, Malta
Center for Neuroscience, Ben-Gurion University of the Negev, Be'er Sheva 8410402, Israel
Epilepsy Research Centre
Ion Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3052, Australia
Epilepsy Research Group, Australian Centre for Precision Health, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
Population Health and Immunity Division, the Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
Department of Medical Biology, the University of Melbourne, Melbourne, VIC 3010, Australia
Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia
Department of Paediatrics, The University of Melbourne, Royal Children's Hospital, Parkville, VIC 3052, Australia
The Florey Institute, Parkville, VIC 3052, Australia
Department of Pharmacology and Vascular Biology and Therapeutics Program, Yale University School of Medicine, 10 Amistad Street, New Haven, CT 06520, USA
Epilepsy Center Bethel, Bielefeld 33617, Germany
The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Boston, MA 02142, USA
Institute of Neurology, University Magna Græcia, Catanzaro 88100, Italy
Neurophysiopathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy
Department of Human Neurosciences, Sapienza University of Rome, Viale dell'Università, 30, 00185 Rome, Italy
Folkhälsan Research Center, Helsinki 00290, Finland
Blueprint Genetics, Espoo 02150, Finland
Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki 00290, Finland
IRCCS Istituto delle Scienze Neurologiche di Bologna, Unit of Neurology, Bellaria Hospital, Bologna 40139, Italy
Unit of Genetics of Neurodegenerative and Metabolic Diseases, IRCCS Istituto Neurologico Carlo Besta Milan 20133, Italy
Dipartimento "G.F. Ingrassia," Università degli Studi di Catania, Catania 95131, Italy
Neurology - Neurophysiology Unit, ASST dei Sette Laghi, Galmarini Tradate Hospital, Tradate 21049, Italy
Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto "G. Gaslini," Genova 16147, Italy
Neurology Unit, Human Neurosciences Department, Sapienza University, Rome 00185, Italy
Department of Neuroscience, Reproductive, and Odontostomatological Sciences, University of Naples Federico II, Naples 80138, Italy
Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland
Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki 00290, Finland.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 60198, Israel
Epilepsy Unit, Schneider Children's Medical Center of Israel, Petah Tiqvah 4922297, Israel
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland
Departments of Neurology and Clinical Neurophysiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34452, Turkey
Genetics Department, Kuala Lumpur Hospital, Ministry of Health Malaysia, Jalan Pahang, 50586 Kuala Lumpur, Malaysia
Issue Date: 1-Apr-2021
Date: 2021-04-01
Publication information: American Journal of Human Genetics 2021; 108(4): 722-738
Abstract: Progressive myoclonus epilepsies (PMEs) comprise a group of clinically and genetically heterogeneous rare diseases. Over 70% of PME cases can now be molecularly solved. Known PME genes encode a variety of proteins, many involved in lysosomal and endosomal function. We performed whole-exome sequencing (WES) in 84 (78 unrelated) unsolved PME-affected individuals, with or without additional family members, to discover novel causes. We identified likely disease-causing variants in 24 out of 78 (31%) unrelated individuals, despite previous genetic analyses. The diagnostic yield was significantly higher for individuals studied as trios or families (14/28) versus singletons (10/50) (OR = 3.9, p value = 0.01, Fisher's exact test). The 24 likely solved cases of PME involved 18 genes. First, we found and functionally validated five heterozygous variants in NUS1 and DHDDS and a homozygous variant in ALG10, with no previous disease associations. All three genes are involved in dolichol-dependent protein glycosylation, a pathway not previously implicated in PME. Second, we independently validate SEMA6B as a dominant PME gene in two unrelated individuals. Third, in five families, we identified variants in established PME genes; three with intronic or copy-number changes (CLN6, GBA, NEU1) and two very rare causes (ASAH1, CERS1). Fourth, we found a group of genes usually associated with developmental and epileptic encephalopathies, but here, remarkably, presenting as PME, with or without prior developmental delay. Our systematic analysis of these cases suggests that the small residuum of unsolved cases will most likely be a collection of very rare, genetically heterogeneous etiologies.
DOI: 10.1016/j.ajhg.2021.03.013
Journal: American Journal of Human Genetics
PubMed URL: 33798445
Type: Journal Article
Subjects: dolichol-dependent glycosylation
epilepsy genetics
progressive myoclonus epilepsy
whole-exome sequencing
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.